Federal rescheduling didn\u2019t lift all boats. It lifted one boat, the medical one, and left adult-use tied to the dock. If you\u2019re buying, selling, or raising money on a cannabis company in 2026, that split is now the biggest single variable in cannabis rescheduling business valuation<\/strong>: a dollar of medical profit and a dollar of adult-use profit are no longer taxed the same way, so they are no longer worth the same.<\/p>\n This guide to cannabis rescheduling business valuation covers what actually changed, why it moves price, and the diligence questions that separate a real medical premium from a seller\u2019s wishful spreadsheet.<\/p>\n In April 2026 the Justice Department issued a final order, published in the Federal Register on April 28, 2026, moving two categories of marijuana from Schedule I to Schedule III: marijuana in drug products that have cleared FDA review, and marijuana subject to a state medical marijuana license. You can read the order on the Federal Register<\/a>.<\/p>\n Everything else, including adult-use marijuana, stayed in Schedule I. DEA held a hearing on broader rescheduling from June 29 through mid-July 2026, and as of late September the administrative law judge\u2019s recommended decision was still pending. So the split is real today, and it could narrow later, which is why any cannabis rescheduling business valuation done this year needs a plan for both outcomes. Our federal cannabis rescheduling 2026 explainer<\/a> tracks the process, and Cannabis Legalization News covered the hearing<\/a> as it happened.<\/p>\n It changes after-tax cash flow, and buyers pay for after-tax cash flow. Section 280E of the tax code only disallows deductions for businesses trafficking in Schedule I or II substances. Medical marijuana under a state license is now Schedule III, so medical activity escapes 280E while adult-use activity does not.<\/p>\n Read the statute yourself at 26 U.S.C. \u00a7 280E<\/a>. It\u2019s one sentence long and it has been eating cannabis margins for years. For medical operators, that sentence stopped applying. For cannabis rescheduling business valuation, that\u2019s the whole ballgame: identical gross revenue can now produce very different net income depending on which license it runs through.<\/p>\n On April 23, 2026, Treasury and the IRS announced how tax guidance will work<\/a> after the order. Two points matter for deal pricing:<\/p>\n That second point is where cannabis rescheduling business valuation gets interesting. A dual-licensed company doesn\u2019t get all-or-nothing treatment. It gets an allocation, and allocations are only as good as the books behind them. We walk through the tax history in 280E retrospective relief for medical marijuana<\/a>.<\/p>\n Pricing a deal around the medical\/adult-use split?<\/strong> Talk to our cannabis M&A counsel<\/a> before the letter of intent locks in a number you can\u2019t defend.<\/p>\n Take two dispensaries with the same revenue and the same operating costs. One sells under a state medical license. The other sells adult-use. The medical store can deduct rent, payroll, and marketing like any normal business. The adult-use store, still under 280E, largely can\u2019t. Same top line, different bottom line, different price. That is cannabis rescheduling business valuation in one sentence.<\/p>\n How big the gap is depends on the target\u2019s cost structure, so we won\u2019t pretend there\u2019s a universal multiple. But the direction is not in doubt, and in our core states it plays out differently:<\/p>\n For the operator-side view of what a medical license is worth, Collateral Base looks at medical license value under Schedule III<\/a>.<\/p>\n A seller claiming a medical premium should be able to answer all five of these with documents, not adjectives.<\/p>\n The order covers marijuana \u201csubject to a state medical marijuana license.\u201d Pull the licenses, then pull the point-of-sale data showing which sales ran under which authority. A store that sells mostly adult-use while holding a medical license is not a medical business for pricing purposes.<\/p>\n If the target runs both programs, Treasury\u2019s apportionment approach means someone has to split shared costs between medical and adult-use. Ask how the target plans to do it and whether its accounting system can prove it. A clean allocation is worth money. A guess is a future audit.<\/p>\n Schedule III activity requires DEA registration, and the new rules give state medical licensees an expedited path. But a DEA registration can\u2019t be assigned or transferred without DEA\u2019s written consent under 21 CFR 1301.52(b)<\/a>. In an asset deal, plan for the buyer to need its own. That\u2019s a new closing condition most cannabis purchase agreements weren\u2019t written to handle.<\/p>\n Has the target filed returns claiming deductions, or amended prior returns? Those positions become the buyer\u2019s problem in a stock or membership-interest deal. Tax reps, a specific indemnity, and escrow sized to the exposure belong in the agreement.<\/p>\n If broader rescheduling pulls adult-use into Schedule III, today\u2019s medical premium shrinks. If the order is narrowed or challenged, it could grow or reverse. Don\u2019t pay a fixed premium for a variable fact. Earn-outs, price adjustments tied to regulatory events, or a lower base price with upside all let the deal flex with the law.<\/p>\n The smartest 2026 deals treat cannabis rescheduling business valuation as two valuations stapled together: one for medical cash flow, one for adult-use cash flow, each with its own tax profile and its own regulatory risk. Then the purchase agreement assigns who carries each risk.<\/p>\n That usually means separate revenue schedules in the reps, a DEA registration covenant, tax indemnities that survive closing, and the usual state change-of-ownership approval as a condition. The state approval side hasn\u2019t changed; our cannabis license transfer rules by state<\/a> hub covers who approves what. The diligence checklist on our cannabis due diligence attorney<\/a> page is the place to start the document request.<\/p>\n In most cannabis rescheduling business valuation work, often yes, because medical activity under a state medical license is now Schedule III and escapes Section 280E, while adult-use activity remains Schedule I. The size of the premium depends on the business\u2019s costs and on how cleanly its revenue is separated.<\/p>\n To the adult-use side, yes. Treasury has said that for businesses with multiple activities, 280E applies only to the Schedule I or II activity, for example by apportioning expenses.<\/p>\n Not automatically. Under 21 CFR 1301.52(b), a DEA registration cannot be assigned or transferred without DEA\u2019s written consent, so buyers should plan for their own registration or for consent as a closing condition.<\/p>\n It could shrink. DEA\u2019s hearing on broader rescheduling finished in July 2026 and a decision is pending. If adult-use moves to Schedule III, the tax gap between the two narrows.<\/p>\n Rescheduling turned one cannabis market into two for tax purposes, and price follows tax. Cannabis rescheduling business valuation is now a two-column exercise. Buyers should demand proof of the medical revenue they\u2019re paying for; sellers with clean medical books should stop accepting adult-use pricing. Either way, get cannabis M&A counsel<\/a> involved before the valuation becomes a signed number.<\/p>\n This article is general information about cannabis business law and federal tax developments as of September 2026. It is not legal or tax advice, and reading it does not create an attorney-client relationship. Rescheduling and IRS guidance are still developing; confirm current law and consult a qualified tax advisor before acting. Howard Law Group advises cannabis clients in Illinois, Missouri, Wisconsin, Michigan, Ohio, New York and Florida.<\/em><\/p>\n \n\t\t\t\t<\/div>\n![\"cannabis](\"https:\/\/www.cannabisindustrylawyer.com\/wp-content\/uploads\/2026\/09\/cannabis-rescheduling-business-valuation-featured-image.jpg\")
<\/figure>\nCannabis Rescheduling Business Valuation Starts Here: What the Order Actually Did<\/h2>\n
How Does Cannabis Rescheduling Change Business Valuation?<\/h2>\n
The Treasury Rules That Drive the Numbers<\/h2>\n
\n
Why a Medical License Can Now Be Worth More in a Cannabis Rescheduling Business Valuation<\/h2>\n
\n
Five Diligence Questions for Cannabis Rescheduling Business Valuation<\/h2>\n
1. What license is the revenue actually under?<\/h3>\n
2. Can the books support an expense allocation?<\/h3>\n
3. Does the target have its DEA registration, and will it survive the deal?<\/h3>\n
4. What tax positions has the target already taken?<\/h3>\n
5. What happens to the price if the law moves again?<\/h3>\n
Structuring Around the Split<\/h2>\n
Frequently Asked Questions<\/h2>\n
Is a medical cannabis license worth more than an adult-use license after rescheduling?<\/h3>\n
Does 280E still apply to dual-licensed dispensaries?<\/h3>\n
Does a buyer inherit the seller\u2019s DEA registration?<\/h3>\n
Could the medical valuation premium disappear?<\/h3>\n
The Bottom Line<\/h2>\n